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Autism Spectrum Disorder (ASD) is a developmental disorder occurring in children from 
a young age and has complex causation. Individuals with ASD present with atypical social-
communication and cognition with restricted and repetitive behaviors (American Psychiatric 
Association [AAP], 2000; American Psychiatric Association [APA], 2013; Carcani-Rathwell et 
al., 2006; World Health Organization [WHO], 1993). U.S. based estimates show the prevalence 
of ASD published by the CDC each year has increased from 1 in 150 children to 1 in 59 from 
2000 to 2014 (Baio et al., 2018; Center for Disease Control and Prevention [CDC], 2019). ASD 
is early forming and is currently considered diagnostically stable at 24 months of age 
(Chawarska et al., 2007; Kleinman et al., 2008; Lord et al., 2006), though the average age of 
diagnosis ranges from 46 to 67 months and varies between socio-demographics (Baio et al., 
2018, Mandell et al., 2006). While variation in delays are not clear, a major factor in diagnostic 
delay is the complexity of early identification process which often requires multiple clinical 
appointments prior to receiving an ASD diagnosis, and much frustration amongst caretakers 
(Goin-Kochel et al., 2006). Ultimately, many children with ASD who are identifiable for an early 
diagnosis are not receiving a diagnosis and the benefits that come with early identification.  
 Early identification of children with ASD is important because it enables children to 
receive resources which can help them achieve better developmental outcomes (Green et al., 
2017; National Research Council [NRC], 2001; Virues-Ortega, 2010). Research shows that 
intervention has larger benefits when performed on younger children with ASD compared to 
older children (Rogers, 1996). For example, studies suggest that interventions for children 
utilized earlier in life have positive effects on IQ development and adaptive behavior 
underscoring the need to identify earlier rather than later (Eldevik et al., 2009; Harris, 2017; 
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Rogers, 1996). Research also shows that children who receive treatment before 48 months are 
more likely to be placed into regular education class than those enrolled after 48 months of age 
(Kasari et al., 2012). Studies that enroll high risk children for ASD to investigate outcomes have 
begun to outline the benefit of the intervention groups even to the point of “reducing prodromal 
ASD symptoms in the second and third years of life” (Green et al., 2017, p. 1337). The evidence 
for the positive impact of earlier received interventions highlights the need for effective early 
identification of children with ASD and potential for ASD. 
Early Identification Process Model 
Early identification involves complex multi-faceted processes informed by insights from 
the public health, education, early intervention and psychometric/clinical literatures (Bricker et 
al., 2013; Sheldrick 2011, 2015, 2016, 2019). Screening/monitoring and identification of 
diagnosed cases are more commonly discussed in public health and epidemiology, whereas 
screener development, assessment tool development, specific intervention implementation, and 
diagnostic training are more commonly discussed in clinical science and psychometric research. 
The process of identification roughly follows the model seen in Figure 1 (Barger et al., 2018). 
The early identification process is typically initiated by monitoring (e.g. brief informal queries 
about development) and screening (i.e. brief formal screeners querying about development) 
wherein children with ASD and related conditions are observed during well-child visits (CDC: 
“Recommendations and Guidelines”, 2019; Individuals with Disabilities Education Improvement 
Act [IDEA], 2004). Screening and monitoring processes (Step A) lead to the second phase where 
individuals who have been determined “at risk” by screening and/or monitoring (Step B) may be 
referred for a clinical assessment (Step C; Filipek et al., 1999). In order to render an ASD 
diagnosis, specialists are then required to administer and score diagnostic assessments (Step C; 
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Klin & Volkmar, 1995; Klin et al., 2005). The fourth phase is the diagnosis phase (Step D), 
wherein licensed clinicians match presenting symptoms to defined diagnostic information, 
preferably as part of a multi-disciplinary team (Klin & Volkmar, 1995; Klin et al., 2005; 
Volkmar et al., 2014a, 2014b). The final phase is treatment receipt. 
 
Figure 1  




Early Identification: Monitoring and Screening 
 Monitoring and screening are the first community based intentional efforts to identify any 
atypical development in children (APA, 2006; Hirai et al., 2018). Monitoring refers to the 
continued surveillance of children’s developmental status by health care providers that may lead 
to referral for services or diagnosis for developmental delay (Barger et al., 2018; Bright Futures, 
2006). Screening refers to a method of determining if a child suspected of having a disability, by 
parent or health care provider, needs early intervention services (Hirai et al., 2018; National 
Research Council, 2001). A U.S. study examining the prevalence of screening in early childhood 
reported that in 2016 fewer than one third of children 9 through 35 months in age had received 
any form of screening (Hirai et al., 2018). Between screening and monitoring, screening is the 
more studied of the two (Barger et al., 2018). 
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ASD screening is considered within the broader context of developmental screening 
wherein a number of social and developmental milestones, including those specific to ASD, are 
considered (NRC, 2001). Developmental screening and monitoring is recommended by several 
federal and professional groups (Bright Futures, 2007; Office of Disease Prevention and Health 
Promotion [ODPHP], 2010; Committee on Children, 2001; Johnson & Myers, 2007).  ASD 
specific screenings are recommended to occur around 18 to 24 months of age as this timeframe 
coincides with the ability to recognize symptoms and the appropriate age of diagnosis (Lord et 
al., 2006; Chawarska et al., 2007; Bright Futures, 2007).  
The tools informing the screening process are referred to as screeners and are designed to 
be reliable for identifying probable cases of their intended population and screening out non-
cases (U.S. Department of Health and Human Services [HHS], 2014). Screeners are meant to be 
brief and used to indicate that an assessment is necessary and not necessarily to provide a 
diagnosis (CDC, 2020; Robins, 2008). Ideally, screeners can be made more accessible by making 
sure they accomodate eight-grade reading levels and are informative enough for assessment 
referral (Arnold et al., 2006). Despite widespread recommendations for screening, screeners are 
often underutilized by pediatricians during scheduled check-ups even though they are an 
important part of early intervention systems (Hirai et al., 2018; NRC, 2001; Sand, 2005).    
There exist different instruments when considering ASD identification screeners; in 
particular, whether screeners are designed for use in the general population or in “at risk” 
populations (Norris & Lecavalier, 2010). Both the general and at-risk populations should be 
screened for developmental delays as cases are present in both levels. Level 1, population-based, 
samples require screeners relevant for low-risk populations where they can be implemented in 
areas like typical well-child visits to try to identify risk for atypical development (Barger et al., 
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2018; Robins, 2008; Zwaigenbaum et al., 2015). The purpose of Level 1 screeners is to increase 
the number of identified children from a population sample who would otherwise continue to be 
unidentified. Level 2, “high-risk”, populations are fundamentally different than Level 1 
screening because these populations typically are already being served or monitored by health 
care providers due to risk for developmental delays (Robins, 2008; Zwaigenbaum et al., 2015).  
Early Identification: Diagnostic Assessment and Diagnosis 
 After the screening process, infants and children are either determined to be low risk for a 
delay or carry moderate/high risk (Klin et al., 2005; Volkmar et al., 2014a). Children with 
moderate or high risk continue from screening clinical assessment phases where relevant 
information such as medical history and diagnostic assessments are gathered (Klin et al., 2005). 
Notably, although ASD can be diagnosed by a single trained clinician, “the clinical assessment 
of individuals with this disorder is most effectively conducted by an experienced 
interdisciplinary team” (Klin & Volkmar, 1995, p. 5; Klin et al., 2005). Once an individual 
continues from the assessment step to the diagnosis step all relevant information from the 
screening and assessment phase becomes evidentiary to support or deny a diagnosis. At this 
stage, diagnosis may be conducted by a single clinician or multiple clinicians who make the 
ultimate clinical decision for a child’s outcome. The gold standard is to incorporate all available 
resources to acquire the most accurate diagnosis which includes multi-disciplinary clinicians as 
well as diagnostic scored assessments (Klin & Volkmar, 1995; Klin et al., 2005).  
The tools of the assessment phase can be used to aid the clinician to determine if 
individuals meet the criteria for ASD (LeCouteur et al., 2007; Klin et al., 2005; Volkmar et al., 
2014a). Two widely recommended instruments in aiding autism assessment and diagnosis are the 
Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule 
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(ADOS) (LeCouteur et al., 2007). The ADOS is a semi-structured standardized assessment of 
four modules on which an individual is observed by clinicians which is intended to “complement 
information obtained from developmental tests and caregiver history” (Gotham et al., 2007). The 
ADI-R is a semi-structured investigator-based interview for caregivers in reference to ICD-10 
and/or DSM criteria (Lord et al., 1994). These instruments have been reported to match 
characteristics in children with DSM-IV diagnosis of autism traits, however DSM-V criteria 
leads to a drop off in diagnosis compared to DSM-IV when using ADOS (Foley-Nicpon et al., 
2017; LeCouteur et al., 2007; Mazefsky et al., 2013; Ventola et al., 2006).  The differences in 
criteria between DSM-IV criteria and DSM-V criteria is estimated to lead to fewer diagnoses of 
children with PDD-NOS and Asperger’s disorder (Smith et al., 2015). 
 Since an ASD diagnosis is heavily reliant on the instruments used and the clinical 
judgement and experience of those rendering the diagnosis (Klin et al., 2005), it is reasonable 
that early identification studies take diagnostic approaches into account. These diagnostic 
approaches include both the multi-disciplinary teams and highly diagnostic instruments like 
ADOS/ADI-R being used in tandem to create a high quality and robust diagnosis. Figure 2 
displays a framework from Barger (2018) for ranking screening accuracy studies.  Two 
subranges exist within this framework: clinical diagnosis exists in the range of adequate to 
excellent while unacceptable to poor exists to explain research studies that measure diagnostic 
accuracy without clear clinical input.  The different tiers represent expected differences of 
quality of diagnosis. Starting from the bottom of the framework, unacceptable indicates that a 
study does not clearly indicate that the child received a formal diagnosis (e.g., assessment scores 
were used to denote a diagnosis, but not clinician); very poor indicates diagnosis based on non-
recommended assessment, but does not indicate a clinician provided a diagnosis; and poor 
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represents no clinical diagnosis but a positive diagnostic result from recommended assessments 
such as the ADOS or ADI-R. Continuing up the framework we reach 3 levels that require 
clinical diagnosis good, very good, and excellent.  The difference between these tiers, all of 
which use multi-informant clinical diagnoses, ranges from: good where no assessments were 
referenced along with the clinical diagnosis; very good where non-widely recommended 
assessments were used and along with a clinical diagnosis, and excellent where multi-informant 
clinical diagnosis method is used in conjunction with widely recommended assessments.  Single 
clinician diagnosis can only be considered good if it is accompanied by an assessment that is not 
widely recommended or very good if it is informed by a widely recommended screener. The 
tiering aims to lay out the difference in quality and why studies should seek to achieve for 
excellent reference standard. This framework is a proposed model and the tiering is based on 
expert reasoning.  
 
Figure 2 






Diagnostic Accuracy and Meta-analysis of Diagnostic Accuracy for Screeners 
ASD screeners and assessments seek to correctly classify individuals with or without a 
condition (Robins 2008). Following the intended purpose, the best measure of a screener and 
assessment is to determine their ability to correctly predict a particular clinical outcome. 
Diagnostic accuracy is the measure of a test’s ability to correctly identify when a condition is 
present or not in an individual (Gatsonis & Paliwal, 2006). Diagnostic accuracy metrics indicate 
the degree to which tools correctly classify people into cases and non-cases.   
A variety of diagnostic accuracy metrics can be developed using the confusion matrix 
seen in Figure 3. Understanding the multi-faceted aspects of accuracy can be aided by filling out 
a confusion matrix like the one shown in Figure 3. Individuals who are screened fall into 1 of 4 
categories based on their screening outcome (positive or negative) and their true condition status. 
The ideal test would correctly show a positive result for all individuals with the condition and a 
negative result for all individuals without the condition. This describes true positives (TP) which 
are positive screens for those with the condition and true negatives (TN) which are negative 
screens for those without the condition respectively. The other two classifications are individuals 
who screen positive but do not truly have the condition (i.e., false positives; FP), and negative 










Figure 3  
Confusion Matrix Accuracy Metrics 
 
 True Positive (TP) False Positive (FP)  
This row represents 
all individuals who 
are indicated to have 
the condition. 
False Negative (FN) True Negative (TN) Positive Predictive 
Value = TP/TP+FP 
This row represents 
all individuals who 
are indicated to not 






Value = TN/FN+TN 
 This column 
represents all 





without the condition 
 
The most common measurements of accuracy are sensitivity and specificity, respectively 
the ability to correctly determine those with the condition among those who truly have the 
condition and the ability to determine those without the condition among those who truly do not 
have the condition (Rothman, 2012). Other metrics for determining accuracy include the positive 
predictive value (PPV) and the negative predictive value (NPV). The PPV finds among the 
number of individuals referred, how many were accurately identified and met criteria to receive 
such referral for a diagnosis, while the NPV does the opposite in that it determines among 
individuals not referred how many correctly needed no referral. Sensitivity, specificity, PPV, and 
NPV can be combined to get metrics that represent the diagnostic ability of the test overall such 
as the positive likelihood ratio (LR+), the negative likelihood ratio (LR), and the Diagnostic 
Odds Ratio (DOR). The positive likelihood ratio (LR+) divides sensitivity by 1-specificity and 
the negative likelihood ratio (LR-) is measured using the reciprocal of LR+. The DOR is a ratio 
of the (LR+) and the (LR-). The usefulness of these tests are their interpretation which for LR+ 
is: the likelihood of a positive test result in a person with a disease is more (or less, in a poorly 
10 
 
designed test) likely in a person with the condition than a person without the condition. 
Similarly, the LR- shows the opposite result: the likelihood of a negative test in a person without 
the condition is more (or less) likely in a person without the condition than a person with the 
condition. Finally, DOR indicates the odds of a person with a condition being correctly classified 
when taking a test.  
Systematic reviews and meta-analyses provide “a transparent and replicable method for 
summarizing the literature” (Pigott 2012, p. 1). A systematic review is a structured review of 
published literature to bring together all relevant studies (Uman, 2011; Siddaway et al., 2019). A 
meta-analysis assesses studies collected from a systematic review quantitatively or qualitatively 
and their quality and findings are reported (Armstrong, 2011; Siddaway et al., 2019; Grant & 
Booth, 2009). The extraction of effect sizes from a systematic review may be combined and 
synthesized into a meta-analysis (Walker et al., 2008). These reproducible studies and combined 
effect estimates provide ways to assemble common studies to drive research and policy forward 
(Walker et al., 2008).  
The best method for screener comparison is a review of the published literature to 
determine the screener with the highest diagnostic accuracy (Gatsonis & Paliwal, 2006). When 
performing a quantitative review such as a meta-analysis, fixed effects or random effects will be 
used. A fixed effects model assumes that there is a true effect size that studies are estimating; 
these models may be used when a meta-analysis combines estimates of closely related studies 
(Borenstein, 2009; Pigott and Polanin, 2020). The corollary to fixed effects is random effects 
where an effect size is “similar but not identical across studies” (Borenstein et al., 2009, p. 69). 
When there is more expected variability between studies a random effects model may be better 
to use; for example, variability may result from differences in study settings or sampling 
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procedures (Borenstein et al. 2009, p. 69). Random effects are recommended for use in most 
meta-analyses (Pigott & Polanin, 2020). When combining the previous topics of meta-analysis, 
diagnostic accuracy, and modeling techniques there are important choices to be made.  
While the choice to utilize random or fixed effects modeling must be made prior to 
running a model, the choice of how to analyze your results (univariate versus multivariate) can 
be made after carefully reviewing the studies. Starting with the fewest variables, the univariate 
approach is conceptually the simplest approach only using one variable to describe an outcome. 
This type of approach can be useful in areas where a controlled system is possible. For example, 
traditional physics and chemistry experiments studying the effect on pressure as temperature 
(one variable) increases. This approach’s strength is that you can make direct assertions about 
the relationship between the dependent and independent variable. The weaknesses are that the 
simplicity of this approach cannot adequately address the complexity of studies that cannot 
control all variables except the ones of interest. 
The multivariate approach is similar to the univariate approach, but instead of one 
variable, more than one variable is used to analyze an outcome or set of data.  By increasing the 
number of variables considered, analyses can more accurately reflect the multiple factors 
impacting an outcome, thus more closely reflect a complex reality.  However, this has the 
potential for negative consequences and predictors for a multivariate model should be chosen 
carefully. If confounded variables are included in a multivariate model misleading results can 
occur. That said, the benefits of multivariate analysis over univariate cannot be understated as 
multivariate approaches can more robustly describe complex relationships, a noted weakness of 




According to Walter and Jadad (1999) meta-analysts have historically employed 
univariate approaches by analyzing sensitivity or specificity independently, but univariate 
approaches do not account for their non-independent negative correlations; multivariate 
approaches do  account for these correlations. Two approaches have been proposed to address 
univariate limitations: the hierarchical receiver operating curve (HSROC) and the Reitsma 
(Harbord & Whiting, 2009). The HSROC is a Bayesian approach that accounts for the 
correlations between sensitivity and specificity (Rutter & Gatsonis, 2001).  The Reitsma random 
effects model allows the sensitivity and specificity to be modeled simultaneously. Both 
approaches can be visualized with graphs displaying sensitivity by 1 – specificity (i.e., FPR). 
Due to their addressing the fundamental limitation of correlated variables and imperfect 
visualizations of traditional univariate analyses, these multivariate approaches are strongly 
recommended (Jackson et al., 2010; Reitsma et al., 2005).   
Modified Checklist for Autism in Toddlers  
As mentioned above there are multiple screeners for ASD; however, few if any are as 
widely researched as the Modified-Checklist for Autism in Toddlers (M-CHAT) (McPheeters et 
al., 2016). The M-CHAT is a population level screener that was developed at Georgia State 
University by Diana Robins PhD. The M-CHAT’s seminal study was published in 2001 and 
since has been suggested for use as a population-based tool (Zwaigenbaum et al., 2015; Robins 
et al., 2001, 2014). The M-CHAT was developed for identifying ASD in population samples and 
uses questions relevant to infant and toddler development to identify red flags consistent with 
ASD indicators. The M-CHAT was revised from its initial 23 questions to 20 questions in the 
population-based version.  A second, follow-up phase was added to confirm the results of the 
first phase (Robins et al., 2014). The original M-CHAT has been translated into 69 different 
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languages as of 2016, adjusted culturally, and validated home and abroad (Brennan et al., 2016; 
Robins et al., 2001, 2014).  A core strength of this screener is that the M-CHAT is free to access 
online (in English and Spanish) and provides an instant feedback score for curious parents 
(Robins et al., 2014). The psychometrics of the M-CHAT are reported to be .911 and .955 for 
sensitivity and specificity for the initial screening stage without follow-up. With follow up the 
sensitivity decreases to .854 and specificity increases to .993 (Robins et al., 2014).  
To date, there have been two systematic reviews and meta-analysis of diagnostic 
accuracy conducted on autism screeners (Yuen et al., 2018; Sanchez-Garcia et al., 2019).  Yuen 
(2018) reviews the M-CHAT critically concluding there is a lack of evidence for use on children 
18 to 24 months of age and high risk children screened with the M-CHAT have a pooled 
sensitivity of 0.83 and pooled specificity of 0.51. Sanchez-Garcia (2019) includes the M-CHAT 
in their conclusion that population based screeners are effective for low risk children under the 
age of 3. Sanchez-Garcia looked at 9 total screeners and found a pooled sensitivity of 0.72 and 
pooled specificity of 0.98 across multiple screeners. These studies somewhat complemented one 
another while Yuen called for more evidence for a specific population, Sanchez-Garcia provided 
broad evidence of screener usage on that population, but not any particular screener.  
The methods of these studies showed strengths in similar and different ways. Yuen’s 
study provided insights by reviewing the grey literature and extracting sample characteristics 
from the studies. Sanchez-Garcia provided a thorough review when it evaluated its study sample 
for publication bias and performed a subgroup of analysis. Both studies used a Bayesian 
approach to their meta-analysis which is a strong method of analysis for this body of work. 
Despite a number of strengths, the studies by Yuen and Sanchez-Garcia have a number of 
weaknesses. Common weaknesses between the studies include both their data sets suffered from 
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data heterogeneity, indicating substantial between-study differences. Further, Sanchez-Garcia 
missed a population-based study by Magan-Maganto et al. (2018) which matched their study 
criteria. Yuen did not include some large studies such as Stenberg et al. (2014) that includes a 
large low-risk sample of children screened by the M-CHAT. While no study is without 
weaknesses, it is important to consider how these could have impacted their results; by leaving 
out studies that matched their respective criteria, these analyses did not consider all available 
information.  
While there are reviews analyzing the true diagnostic ability of the M-CHAT, to our 
knowledge there is no study investigating the impact of reference standard categories on 
accuracy metrics. This study proposes to categorically analyze studies that screen and diagnose 
children with autism using the Barger reference standard framework. This study seeks to answer 
if there is a relationship between reference standard category and reported screening accuracy. 
Our specific hypothesis is that there is an inverse relationship between screening accuracy and 
reference standard category – in that Multi-Clinician reference standard tier will report the 





The structure of this systematic review was based on the “Preferred Reporting Items for 
Systematic Reviews and Meta-Analysis” (PRISMA) (Moher, 2009). 
Study Criteria 
The papers selected for this study contained information to determine diagnostic accuracy 
for unique ASD screenings using the M-CHAT and with diagnosis information using a clear 
reference standard in both population based and high-risk samples. A requirement of these 
studies is that the study is in English and TP, TN, FP, FN must be made available and clear in the 
study, either in a flowchart or clearly described within the study. For studies whose population 
samples were identical, only one study was included where the population size was the largest; if 
studies were the same size the original study results was given preference.  
Search Criteria 
Three searches were performed for complete coverage of the timeline April 2001 to 
December 31, 2019 the initial on August 2nd, 2019, a prospective search on October 17, 2019 and 
a final review search on February 1, 2020. The search terms for this study were “Modified 
checklist for autism in toddlers” OR MCHAT OR M-CHAT. The initial and final search used 
Web of Science, EBSCO, and ProQuest. In EBSCO the following were searched: Academic 
search complete, Alt health watch, Child Development and Adolescent Studies, CINAHL Plus 
with full text, consumer health complete, Education source, ERIC, family and society studies 
worldwide, Fuente academia premier, Health source nursing academic edition, medline, medline 
with full text, mental measurements yearbook, professional development collection, psych 
articles, psychology and behavioral sciences collection, psychinfo, psychtests, and social work 
16 
 
abstracts; ProQuest: dissertations and thesis at GSU, ProQuest central, arts and humanities, New 
Zealand, biological science, consumer health database, continental Europe, east Europe, central 
Europe, education database, health and medical collection, India, Latin American, Iberian, 
middle east and African, nursing and allied health, public health database, publicly available 
science, social science, UK and Ireland, ProQuest dissertation and thesis, social science 
premium, and education. All articles starting from April 2001 were reviewed for relevance in all 
countries, in English. The ancestral search included a traditional bibliography search of articles 
ultimately deemed to fit inclusion criteria. A prospective search was also performed on all 
articles deemed to fit inclusion criteria via identifying relevant articles using the “cited by” 
feature of Google Scholar.   
The following describes the process for data abstraction of the initial, ancestral and 
prospective searches. After collecting the titles and abstracts in the three searches the collected 
studies underwent a title/abstract review for M-CHAT screening studies.  Studies were screened 
green to be included, yellow to be reviewed a second time and red to be screened out. To check 
on this initial screen-out process, 26 titles and abstracts were randomly selected and coded by an 
independent reviewer - good agreement was found (K = 0.77).   The process then follow that 
pdfs from yellow and green highlighted studies had a full text review performed for the 
inclusion/exclusion criteria, the studies were organized in keep remove computer files for quality 
control.  
Inclusion Criteria 
Studies were included if they fit the following criteria: they included M-CHAT data, they 
were in English, their TP, TN, FP, and FN data was included, and had at least 10 participants. 
The characteristics of these studies were independently reviewed by two separate researchers in 
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order to verify their qualities and assure that all studies that match inclusion criteria are included. 
Search terms and date information was preserved through the search engine account features 
using the “save search” tool. Disagreements between study qualities were resolved by a third-
party researcher blind to either initial party’s decision and the third party decision served as 
tiebreaker.  
Methodologic Quality 
These studies entered an assessment known as Quality Assessment of Diagnostic 
Accuracy Studies-2 (QUADAS-2) which assesses the quality of the study based on potential 
sources of bias in diagnostic accuracy studies. Using appendix F questions of the QUADAS-2 
the domains of patient selection, interpretive bias, criterion assessment, and Domain 4: Flow and 
Timing are reported for low, high, or unclear amount of bias. A “low” bias score was determined 
for all domains where all questions receive a “yes” score and a “high” bias score was determined 
for all domains where one or more questions receive a “no” or “unclear” bias score. The process 
followed this method: All information of the QUADAS-2 appendix F was coded by myself for 
all studies included in the sample set, this file was preserved for quality control.  The next round 
was conducted by Dr. Barger where a randomized sample of 10 studies were selected and coded, 
this file was preserved for quality control. The preserved files between myself and Dr. Barger 
were compared for any discrepancies between individual QUADAS-2 domain items that did not 
meet 100% agreement. QUADAS-2 domain items that did not meet 100% agreement resulted in 
a focused review of all 24 studies for the particular domain items in that were not in agreement. 
For QUADAS-2 sections about appropriate interval between index test and reference standard 
the reviewers determined that any amount of time passed 1 year for positive screens was not 
appropriate and would be marked with the high bias option. Any review questions asked that 
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were not directly answered by the study in clear terms was marked unclear. During the 
QUADAS-2 review only the methods and results sections of included studies were reviewed for 
relevant material to answer the QUADAS-2 domain items. 
Reporting 
The information used for calculating diagnostic accuracy was collected from the selected studies. 
The information of TP, TN, FP, and FN, the screening level, and reference standard from the 
original studies was directly transcribed and recorded for data analysis. As seen below in Figure 
4, the scale used in Barger et al. (2018), was adapted for this study and reference standard rank 
was recorded where each study matched the reference standard grouping.  The original 
framework mixed multi-clinician and single-clinician criteria in the Excellent, Good and Very 
Good rankings. This adapted framework distinguishes multi and single from one another placing 
any multi-clinician criteria above that of any single-clinician criteria. 
Starting from the bottom of the framework, unacceptable, very poor, and poor have not 
been changed from the original. Continuing up the framework have been changed good, very 
good, and excellent.  The difference between these tiers, are that multi-clinician diagnosis is now 
only in excellent and good while single-clinician now only exists in a new category Adequate.  
Specifically the categories are: good where single clinician diagnosis was used in conjunction 
with or without recommended assessments; very good where multi-clinician diagnosis was 
performed with non-widely recommended assessments or no assessments; and excellent where 
multi-informant clinical diagnosis method is used in conjunction with widely recommended 







Redesigned Framework for Categorical Assessment of Reference Standards 
 
Study Variables 
 M-CHAT. The primary outcome variables included diagnostic accuracy outcomes that 
could be derived from confusion matrices. The M-CHAT has an initial screening phase and a 
follow up phase as well as two methods for determining positive criteria. The data for the initial 
phase and follow-up stages were combined in studies where it was necessary, creating only 1 
data set per M-CHAT screening sample. To do this, data was assessed from flow charts to 
accurately report the TP, TN, FP, and FN of the final results and not any one stage specifically. 
The data reported by the study was transcribed for data analysis. The complete original 23 
question M-CHAT can be found in Appendix C. 
Other variables abstracted included: Author, study year, M-CHAT version (original or 
revised), study country, initial screen or follow up, reported screen cut-off, tested positive, tested 
negative, loss to follow up, TP, TN, FP, FN, number with condition, number without condition, 
total N, study reported sensitivity, study reported specificity, study reported PPV, study reported 
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NPV, study reported LR+, diagnostic system, diagnostic assessment tool used, diagnosis 
determined by, publication style, study level, and QUADAS-2 criteria. Diagnostic system 
categories included DSM-IV, DSM-V, ICD-9, ICD-10. Diagnostic assessment tools included 
ADOS, ADI-R, Social Communication Questionnaire (SCQ), Vineland Adaptive Behavior Scale 
(VABS), Childhood Autism Rating Scale (CARS), Bayley Scales of Infant Development 
(BSID),  and Parents’ Evaluation of Developmental Status (PEDS). Determination of diagnosis 
was noted as multiple clinicians, a single clinician, ADOS or ADI-R cut-off, other screener cut-
off, or unclearly reported. Study levels were reported as population based or high-risk. Data on 
diagnostic measure and diagnostic determination were combined to develop proxy variables 
measuring Barger et al.’s (2018) reference rating metric. Two independent raters coded 9 
randomly selected studies and had perfect reliability on Study Year (K = 1.0), good agreement on 
Diagnostic System (K = .75), Moderate to Perfect agreement on Diagnostic Assessment tools 
(Krange = .41-1.0), Moderate agreement for multiple/single clinician (K = .50), and Substantial 
agreement for population/high-risk categories (K = .94).  
Analysis  
 Using the Meta-Analysis of Diagnostic Accuracy (MADA) package in R, the diagnostic 
accuracy metrics of sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV), and Diagnostic Odds Ratio (DOR) were assessed using the data collected from the 
original studies. Bivariate Reitsma models were selected for this analysis which is a random 
effects model and was specified in the MADA package by specifying the Reitsma function. For 
reference standard analysis two groups were made, a combination of the multi-clinician groups 
of excellent and good, referred to as Multi-Clinician, and a combination of adequate, poor, and 
unacceptable, referred to as Other. Results were recorded and reported using Tables 2-7 and 
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Figures 4-15 below. The relatively small universe of available studies resulted in the decision to 




 As described in Figure 5 the database search yielded 2,169 studies and the ancestral 
search yielded 1,462 studies. 3,422 studies were either duplicates or were excluded through the 
title and abstract search and 209 studies were accessed for their full text qualities. 22 studies 
were finally included in the analysis. Two publications reported data on multiple independent 
samples within each manuscript (each had two independent samples). Thus, we report analyses 
on 24 data-sets across 22 total studies. Of these 24 sample sets 15/24 (62%) are population based 















PRISMA Flowchart of Study Selection 
   
 The characteristics of the included studies are presented in Table 1. All identified studies 
were published between 2008 and 2019, and were conducted across 14 countries. The wide range 
of diagnostic measures used are also available for analysis. The ADI-R and ADOS are the most 
commonly reported 13/22 (59%) studies that use them because they are widely recommended 
instruments.  There are 24 sample sets of which 15/24 (62%) are population based and 9/24 
(38%) are clinical/high risk samples.  There are 4 Excellent, 3 Good, 11 Adequate, 2 Poor, and 2 
Unacceptable studies ranked by reference standard criteria. 
 
Exclusion 
- Study does not use the M-CHAT  
- Study does not include data on true 
positives/true negatives  
- Study includes data on accuracy 
metrics but the numbers are not 
consistent across the published study 





Table 1  
Summary of Included Study Characteristics 
Study Year  Country Study Type Clinical Description Diagnostic Measure  Diagnosis  
Rank Based on 
Figure 4 
 Baduel et al. (2017) 2017 France Population Based/General Population   ADOS, VABS, PEP-R Single Clinician Adequate 
 
Canal-Bedia et al. (2011) 2011 Spain Population Based/General Population   ADOS, VABS Multiple Clinicians Excellent 
Chlebowski et al. (2013) 2013 USA Population Based/General Population   
ADOS, ADI-R, VABS, 
CARS Single Clinician Adequate 
Coelho-Medeiros et al. (2019) 2019 Chile High-Risk 
Flagged by 
pediatricians ADOS 
Unsure - Unclearly 
Reported Poor 
Cuesta-Gomez et al. (2016) 2016 Argentina Population Based/General Population  None 
Unsure - Unclearly 
Reported Unacceptable 
Guthrie et al. (2019) 2019 USA Population Based/General Population  Unclear Single Clinician Adequate 
Hoang et al. (2019) 2019 Vietnam Population Based/General Population   None Multiple Clinicians Good 




Table 1 (Continued) 
       
Study Year  Country Study Type Clinical Description Diagnostic Measure  Diagnosis  
Rank Based on 
Figure 4 
Kerub et. al. (2018) 2018 Israel Population Based/General Population  None 
Unsure - Unclearly 
Reported Unacceptable 
Kondolot et. al. (2016) 2016 Turkey Population Based/General Population  CARS Single Clinician Adequate 
Magan-Maganto et. al. (2018) 2018 Spain Population Based/General Population  ADOS, VABS Single Clinician Adequate 
Matson et al. (2013) 2013 USA High-Risk 
Early intervention 
system  None Single Clinician Adequate 
Nygren et al. (2012) 2012 Sweden Population Based/General Population   ADOS, VABS Multiple Clinicians Excellent 
Oien et al. (2018) 2018 Norway Population Based/General Population  ADOS, ADI-R 
Unsure - Unclearly 
Reported Poor 
Oner & Munir (2019) 2019 Turkey Population Based/General Population  ADOS Single Clinician Adequate 
Snow & Lecavalier (2008) 2008 USA High-Risk 
Specialty clinic 
referrals ADOS, ADI-R Multiple Clinicians Excellent 
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Table 1 (Continued) 
       
Study Year  Country Study Type Clinical Description Diagnostic Measure  Diagnosis  
Rank Based on 
Figure 4 
Srisinghasongkram et al. (2016) 2016 Thailand High-Risk 
Identified with 
language delay None Multiple Clinicians Good 
Sturner et al. (2013) 2013 USA High-Risk 
 Testing at an 
Autism Center ADOS Single Clinician Adequate 
Toh et al. (2018) 2018 Malaysia Population Based/General Population   None Single Clinician Adequate 
Topcu et al. (2018) 2018 Turkey High-Risk 
 Social Pediatrics 
Department Ankara 
University None Single Clinician Adequate 
Tsai et al. (2019) 2019 Taiwan High-Risk 
Referred from Child 
Development 
Clinics None Multiple Clinicians Good 
Wong et al. (2018) 2018 Taiwan High-Risk 
Suspected 
developmental 
delays from home 
visits ADOS Single Clinician Adequate 
 




Figure 5 was created with QUADAS-2 bias assessments for each study’s methodological 
quality.  The “Flow and Timing” stands out as the category with a large majority (18/22, 81.8%) 
of studies with high bias for these studies with reference standard the second highest bias group 
with 10/22 (45.5%). The other two QUADAS-2 domains provide a large majority of studies 
matching low bias criteria for qualitative assessments. This qualitative assessment means that up 
to a quarter of studies are questionable for inclusion in the quantitative analysis. 
Figure 5 
QUADAS-2 Results  
 
Diagnostic Accuracy of Screening Tools 
The accuracy of screening tools was evaluated in 22 peer reviewed publications reporting data on 
24 independent samples utilizing the M-CHAT for screening population based or high-risk 
samples. The full collected study metrics are shown in Table 2 below. As described in Table 3 
the pooled sensitivity was 0.782 (95% CI 0.663-0.867) and the pooled specificity was 0.980 
(95% CI 0.941-0.988). The LR+ was 41.826 (95% CI) and the DOR was 192.100 (95% CI 
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76.267 – 483.858).. The reported Se of each study varied between 0.18 and 1.00 and the Sp 
varied between 0.38 and 1.00. 
Table 2 
Reported Study Accuracy Metrics as Reported by Collected Studies 
Study Year  TP TN FP FN Sensitivity Specificity PPV NPV LR+ 
Baduel et al. (2017) 2017 12 1201 8 6 0.67 0.99 0.60 1.00 100.75 
Canal-Bedia et al. 
(2011) 2011 6 2024 25 0 1.00 0.99 0.19 1.00 81.96 
Canal-Bedia et al. 
(2011) 2011 23 2394 63 0 1.00 0.97 0.27 1.00 39.00 
Chlebowski et al. 
(2013) 2013 92 18269 79 6 0.94 1.00 0.34 1.00 218.03 
Coelho-Medeiros et 
al. (2019) 2019 1 90 1 0 1.00 0.83       
Coelho-Medeiros et 
al. (2019) 2019 17 0 3 0 1.00 0.83       
Cuesta-gomez et al. 
(2016) 2016 1 402 1 0           
Hoang et al. (2019) 2019 129 17021 118 1 0.99 0.99 0.51 1.00 144.13 
Kamio et al. (2014) 2014 20 1683 24 22 0.48 0.99 0.45 11.00 33.43 
Kerub et al. (2018) 2018 7 1538 43 3 0.70 0.98 0.20 1.00   
Kondolot et al. (2016) 2016 2 2004 15 0 1.00 0.99 0.12 1.00 134.60 
Magan-Maganto et al. 
(2018) 2018 9 3485 10 2 0.82 1.00 0.08 1.02 285.95 




Table 2 (Continued) 
Study Year  TP TN FP FN Sensitivity Specificity PPV NPV LR+ 
Oien et al. (2018) 2018 69 67969 1402 228           
Oner & Munir (2019) 2019 57 6388 95 0 1.00 0.91 0.09 1.00   
Snow & Lecavalier 
(2008) 2008 38 5 8 5 0.88 0.38 0.83 0.50 1.44 
Srisinghasongkram et 
al. (2016) 2016 49 785 2 5 0.91 1.00 0.96 0.99 357.06 
Sturner et al. (2013) 2013 23 4568 17 16 0.59 1.00 0.38 6.22 159.06 
Topcu et al. (2018) 2018 3 465 15 0 1.00 0.92 0.07 1.00  
Tsai et al. (2019) 2019 19 273 17 3 0.88 0.94 0.61 0.99  
Wong et al. (2018) 2018 65 115 58 14 0.46 0.93  1.92  
Oien et al. (2018) 2018 69 67969 1402 228           
Oner & Munir (2019) 2019 57 6388 95 0 1.00 0.91 0.09 1.00   
Snow & Lecavalier 
(2008) 2008 38 5 8 5 0.88 0.38 0.83 0.50 1.44 
 
The reported TP, TN, FP, and FN of table 2 were used to calculate sensitivity, Sp, and 
DOR for all studies which can be seen in Figures 6,7, and 8. The forest plots in Figure 6 show 
substantial variability in sensitivity with a minimum point estimate of 0.23 and a maximum of 
0.99. For Sp many studies show highly specific estimate with fewer exhibiting large confidence 
intervals, the min. was 0.39 and max. was 0.99.   
 
 
Figure 6  















Meta-Analysis Estimates All Studies 
 Point Estimate 95% Lower Bound 95% Upper Bound 
DOR 192.100 76.267 483.585 
Pooled Sensitivity 0.782 0.663 0.867 
Pooled Specificity 0.980 0.954 0.991 
 
Exploration of Heterogeneity  
 Using the Cochran Q test, the DOR of 24 data sets were assessed for heterogeneity and 
the results were found to be 28.47 (df = 23, p = 0.198) which shows there is insubstantial 
heterogeneity in the sample. However, Study Type level analyses were planned a priori and thus 
conducted.  In addition to the Cochran Q test, the spearman rho correlation between sensitivity 
and false positive rate (FPR) is 0.184 (-0.237, 0.547). This suggests there are no threshold effects 
between sensitivity and FPR in this analysis (though, as previously mentioned, there is low 
power).  
Using all 24 sets of data an SROC curve was constructed displaying sensitivity and FPR. 
The studies were similar in that all M-CHAT scoring was based on suggested original cut-off 
values proposed by Robins (2001, 2014) except one study, Kamio et al. (2014). A variation 
between the studies collected was whether or not they used solely the M-CHAT’s initial stage, 
the follow-up stage or a combination of the two. The prediction region shows a wide range for 
both FPR and sensitivity when considering all studies. Figure 9 demonstrates that studies vary in 
their results even though they all report on M-CHAT screening. Figure 10 shows the entire 
sample of studies sensitivity related to the FPR visualized as an SROC. The 95% interval is 
situated above 0.6 sensitivity and less than 0.1 FPR. There are four notable studies with low 
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FPR; it is noteworthy is that all four are high-risk studies (Coelho-Modeiros et al., 2019; Matson 
et al., 2013; Snow & Lecavlier, 2008; Wong et al., 2018). 
Figure 9 






Bivariate Reitsma SROC of All Included Studies 
 
Subgroup Comparisons 
Population vs. Clinical Study Types 
 Even though the data was not found to be heterogeneous based on the Cochrane Q test, 
subgroup comparisons were performed between the studies examining general populations and 
those examining clinical populations. When examining Figures 6, 7, and 8 again the studies are 
organized first by Study Type, population based first and then high-risk, in order to visually 
describe similarities by Study Type. The clinical studies display substantially lower and different 
sensitivity and specificity than population based studies this is shown in Figure 6 and 7.  
 The forest plot of Figure 6 shows variability in the sensitivity of the studies as a whole, 
but assessing the sensitivity by population based or high-risk reduces the variation and partially 
explains some Study Type relationship. A similar visual description is seen in Figure 7 where 
35 
 
variability is largely contained by the high-risk studies, and Figure 8, where the DOR is high and 
significant for all population based studies but some high-risk show non-significant results. The 
population specificities have a tight range from 0.92 to 1.00 while the clinical has a much wider 
range of estimates. Splitting these by their subgroups has helped to clarify the differences 
between these two study types when describing their sensitivity and specificity. Examining the 
high-risk studies once again, in Figure 8, shows more variability where one study, Matson 
(2013), had a DOR of less than 1.0 with a confidence interval that did not cross 1.0 indicating a 
significant result.  
When inspecting the numbers closer, Table 4 serves to show the specifics of the 
univariate characteristics of data sets when they are split. The summary estimates that are used in 
Figures 6, 7, and 8 are shown here more clearly with their confidence intervals (95% CI). For 
population based studies the pooled sensitivity was 0.746 (0.555, 0.874) and the pooled Sp was 
0.992 (0.985, 0.995). The estimate of sensitivity for the high-risk study types (0.821 (0.701, 0.900) 
is higher than the population based counterpart, but has a lower estimate for specificity 0.906 
(0.639, 0.981). The difference in DOR between the two is large as well with a population DOR of 
396.756 (126.753, 1241.906) and high-risk of 58.389 (8.318, 409.866). Like with the full sample 












Univariate Statistical Measures of Included Studies by Study Type 
 Population df p-value Clinical df p-value  
k 15   9    
Equality of 
Sensitivities 
364.986  14 <0.001 56.8563 8 <0.001  
Equality of 
Specificities  
4586.487  14 <0.001 2621.484 8 <0.001  
Rho (95% CI) -0.388 (-0.725, 0.211)   0.114 (-0.595, 0.723)    
DOR (95% CI) 396.756 (126.753, 
1241.906) 
  58.389 (8.318, 409.866)    
Cochran’s Q  13.488  14 0.489 6.95 14 0.542  
Tau of DOR 
(95% CI) 
2.055 (0.000, 2.551)   2.811 (0.000, 4.388)    
Tau2 of DOR 
(95% CI) 
4.221 (0.000, 6.508)   7.901 (0.000, 19.258)    
Sensitivity 
(95% CI) 
0.746 (0.555, 0.874)   0.821 (0.701, 0.900)    
Specificity 
(95% CI) 
0.992 (0.985, 0.995)   0.906 (0.639, 0.981)    
 
The following tables represent the meta-regression analysis.  Table 5 reports the log 
likelihood of each model and the comparison to the null model.  The log likelihood of the model 
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incorporating Study Type (population based and high-risk) is 64.075. The Chi-squared analysis 
of the model is significant at p = 0.004 showing that Study Type model explains some of the 
heterogeneity between included studies. Finally Table 6 shows the meta regression table for 
Study Type. For the Study Type model the regression coefficient for the FPR is significant, 




Regression Model Performance Comparison Characteristics 
 Study Type 
 Model Null Model 
Log Likelihood 64.075 57.850 
df 7 5 
k 2 2 
AIC -114.149 -105.699 
BIC -101.051 -96.343 
CHI-SQ (df, p-value) 10.84 (2, 0.004*)  
Note. Significant p-value set at α=0.10 
Table 6 
Bivariate Meta-Regression Coefficients  
 Estimate 2.5% CI 97.5% CI p-value 
Study Type Model 
Sensitivity (Intercept) 1.673 0.712 2.634 0.001* 
Sensitivity Population Based -0.647 -1.871 0.577 0.300 
FPR (Intercept) -2.343 -3.508 -1.179 0.000* 
FPR Population Based -2.443 -3.904 -0.982 0.001* 
Note. The control group for the Study Type model is High-Risk samples. 
 
 
Multi-Clinician vs Other Reference Standard 
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 Figures 11, 12, and 13 show the sensitivity, specificity, and DOR with summary 
estimates when organized by reference standard level. These forest plots are very similar to 
Figures 6, 7, and 8 for use describing the breakdown of these two groups visually. When 
observing these studies organized by Multi-Clinician and Other there appears to be variability in 
both levels of reference standard quality. Sensitivity shows high variability throughout the 
studies in Figure 11 while Specificity shows less variability overall in Figure 12. Unlike the 
Study Type breakdown, where most variability was seen in the high-risk studies, the variability 
of Reference Standard does not appear to be represented by one level more than the other. Using 
Table 7 The pooled sensitivity estimate of Multi-Clinician reference standard in 0.874 and the 
pooled estimate of Other is 0.711.  The CI regions of these estimates overlap but the point 
estimate difference is 0.163 for sensitivity. The specificities on the other hand are very similar, 
0.983 and 0.978 for Multi-Clinician and Other respectively. Finally, the DORs are 460.927 and 
121.330 for Multi-Clinician and Other respectively show a large difference between the two 
point estimates and a much higher DOR for Multi-Clinician.  
Descriptive characteristics of these groupings of data are the Cochran Q test and Spearman’s 
Rho. The Cochran’s Q shows a non-significant result indicating no heterogeneity within the 
groupings of excellent and good or the grouping of adequate, poor, and unacceptable. 
Spearman’s rho for these sets of data are 0.102 (-0.649, 0.753) and 0.247 (-0.283, 0.662) both 
non-significant results and indicating no threshold effects between sensitivity and FPR in either 



















Table 7 shows the univariate characteristics of data sets when they are split by Reference 
Standard level. The summary estimates that are used in Figures 11, 12, and 13 are shown here 
more clearly with their confidence intervals. For Multi-Clinician studies the pooled sensitivity 
was 0.874 (0.711, 0.951) and the pooled Sp was 0.983 (0.927, 0.996) which is higher than the 
estimate of sensitivity and specificity for the Other reference standard study types, 0.711 (0.552, 
0.831) and 0.978 (0.939, 0.992). The difference in DOR between the two is large as well with a 
Multi-Clinician DOR of 460.927 (73.658, 2884.340) and Other DOR of 121.330 (42.312, 347.913). 
Finally, Cochran’s Q and Spearman’s rho are non-significant for both of these sets of studies. 
Table 7 
Univariate Statistical Measures of Included Studies by Reference Standard 
 Multi-Clinician df p-value Other df p-value 
k 8   16   
Equality of Sensitivities  83.797  7 <0.001 291.9054  15 <0.001 
Equality of Specificities  748.783  7 <0.001 7423.318  15 <0.001 
Rho (95% CI) 0.102 (-0.649, 0.753)   0.247 (-0.283, 0.662)   
DOR (95% CI) 460.927 (73.658, 
2884.340) 
  121.330 (42.312, 
347.913) 
  
Cochran’s Q  7.008 7 0.428 20.253 15 0.162 
Tau (95% CI) 2.491 (0.000, 4.617)   1.929 (0.000, 3147)   
Tau2 (95% CI) 6.204 (0.000, 21.314)   3.720 (0.000, 9.902)   
Sensitivity (95% CI) 0.874 (0.711, 0.951)   0.711 (0.552, 0.831)   




Table 8 shows the comparison of the Reference Standard model to the null model.  The 
CHI-SQ analysis is not significant for this model, (p = 0.240). This model regressed on 
Reference Standard does not substantially explain the heterogeneity of these studies more than 
the null model. Table 9 shows the results of the meta-regression as a regression table for 
Reference Standard model.  For the Reference Standard model neither regression coefficient is 
significant indicating neither reference standard ranking of Multi-Clinician or Other offers 
significantly better sensitivity or FPR. However, these findings should be judged in light of the 
low power of the study and that we considered p < .10 to indicate potentially meaningful 
relationships; the Reference Standard analysis indicates a trend may be present wherein studies 
with Multi-Clinician reference standards have higher sensitivities than those without.   
Table 8 
Regression Model Performance Comparison Characteristics 
 Reference Standard 
 Model Null Model 
Log Likelihood 60.466 57.850 
df 7 5 
k 2 2 
AIC -106.932 -105.699 
BIC -93.833 -96.343 
CHI-SQ (df, p-value) 2.855 (2, 0.240)  
Table 9 
Bivariate Meta-Regression Coefficients  
 Estimate 2.5% CI 97.5% CI p-value 
Reference Standard Model 
Sensitivity (Intercept) 1.913 0.930 2.897 0.000* 
Sensitivity Other -0.999 -2.213 0.214 0.107 
FPR (Intercept) -4.034 -5.523 -2.545 0.000* 
FPR Other 0.243 -1.585 2.071 0.794 
Note. The control group for the Reference Standard Model is Multi-Clinician reference standard. 
 
 
 Diagnostic accuracy metrics differ between population and clinical studies as illustrated by 
Table 4 and in the bivariate Reitsma illustrated in Figure 14. The population based and high-risk 
study samples can further be broken up by reference standard quality categories. This further 
analysis can be observed in Appendix D where Supplemental Figure 1 and 2 show SROC plots 
of population based and high-risk studies by reference standard criteria. When assessing the 
population-based studies by sensitivity and FPR (1-specificity), they are all grouped near 0 FPR, 
but widely variable when assessed by sensitivity. The high-risk studies are variable in both 
sensitivity and false positive rate indicating these types of studies may vary on more between 
them in terms of study variance. 
Figure 14 
Comparison of Bivariate Reitsma models for Population Based and High-Risk Studies Through 
SROC 
 
 Finally, the last subgroup comparison, Reference Standard, is shown in Figure 15 where 
the studies have been split into groups based on their strength of reference standard. While the 
proposed framework of ranking screening accuracy studies has 6 levels, the studies of this 
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systematic review only identified reference 5 levels of reference standard: Excellent, Good, 
Adequate, Poor and Unclear. These were split into Multi-Clinician and Other categories. The 
SROC ellipse shows Multi-Clinician and Other overlap however the Multi-Clinician group 
appears to be better than the Other category.   
Figure 15 
Comparison of Bivariate Reitsma models for Multi-Clinician and Other Reference Standard 








This study identified 24 samples across 22 peer-reviewed publications reporting data on 
TP, TN, FP, and FN from which we conducted a MADA. The combined accuracy was 
summarized by the bivariate Reitsma model. The results of the full combined study sample 
analysis shows a summary estimate of 192.100 (95% CI 76.267, 483.858) indicating that the 
odds of a positive result on the M-CHAT is 192 times more likely on a patient with ASD than on 
a patient without ASD. Other than DOR the LR+ was 37.368 indicating positive cases were 
likely to be indicated by a positive test result and the LR- was 0.337 indicating that positive cases 
were not likely to be indicated by a negative test result. Despite the fact that our heterogeneity 
scores did not indicate any significant between-study heterogeneity, the decision was made a 
priori to split the studies by the level at which their populations were collected, population-based 
vs high-risk. This knowledge was informed by Tipton et al. (2019) who recommend best practice 
of reducing confounding by separating moderators which may have an association with one 
another; in this case study level of population based and high-risk samples. The meta-regression 
showed that population-based samples have significantly lower FPR than high-risk studies. More 
generally, when compared to clinical studies, population-based studies appear to show much 
higher DOR, 396.756 (126.753, 1241.906) than high-risk studies, 58.389 (8.318, 409.866) and 
pooled specificity, 0.992 (0.985, 0.995) to 0.906 (0.639, 0.981) but a lower pooled sensitivity 
0.746 (0.555, 0.874) than the high-risk studies 0.821 (0.701, 0.900).  
While population based vs high-risk was an expected sample difference, the main focus 
of this study was clinical reference standard. We conducted an additional meta-regression of 
reference standard showing that while we hypothesized an inverse relationship between 
reference standard, this was not fully explored due to the low power of this universe. Instead, we 
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conducted a meta-regression between Multi-Clinician reference standards and Other which 
yielded interesting data. The Multi-Clinician reference standard showed a higher DOR 460.927 
(73.658, 2884.340), sensitivity 0.874 (0.711, 0.951), and specificity 0.983 (0.927, 0.996) than the 
Other group’s results of 121.330 (42.312, 347.913), 0.711 (0.552, 0.831), 0.978 (0.939, 0.992), 
respectively. The DOR and sensitivity differences appear to be large, however the specificity 
differences are quite small. This binary split shows a positive relationship between multi-clinician 
outcomes and reference standard quality, however this result was not significant when performing a 
meta-regression. Ideally the number of studies included would give sufficient power to every 
reference standard category. This study has too few studies per group and so a grouping 
technique, Mutli-Clincian and Other, was employed to increase the size of the categories.Even 
when employing this technique the power remains low. Collectively, these results indicate that 
there is not a significant difference between Multi-Clinician reference standard and Other when 
determining sensitivity and FPR, though meta-regression suggested a trend.   
A secondary analysis was attempted when studies were split by Study Type. These results 
are displayed in Appendix D. A meta-regression was not performed on this data, due to low 
power.  If this work is analyzed only visually, the relationships apparent show a small difference 
in the sensitivity between population based samples who employ Multi-Clinician reference 
standards over Other but not much difference in FPR. For High-Risk samples the sensitivity once 
again is favored by Multi-Clinician, however FPR is significantly different between these two. 
The high-risk sample included 9 studies total which may bias these results. The conclusion 
reached from this analysis is that these results can be viewed as preliminary. The relationship 
between Reference Standard within population based or high-risk studies should be pursued by a 




 This study is unique in the universe of screener reviews in a number of different ways. 
First, this study includes both a study that Sanchez-Garcia missed, Magan-Maganto and a sample 
that Yuen missed. Yeun also notes Stenberg et al. (2014), but our study includes this sample in 
Oien et al. (2018). Furthermore, of the existing quantitative reviews none explore the effect of 
high-risk vs population studies or reference standard effects on diagnostic outcomes. Despite its 
non-significance, this analysis helps underscore that studies utilizing different reference 
standards might impact diagnostic outcomes, and should be considered for other MADA studies.  
The particular focus on the M-CHAT is important as recent research from Guthrie et al. 
(2019) indicates that the current published screener studies have identified too few cases and 
long term follow-up shows the M-CHAT has a lower rate of accuracy than initially thought. 
Specifically, their calculated sensitivity was 0.388 and specificity was 0.949, which is 
substantively lower than sensitivity of .911 and specificity of .955 as reported by Robins et al. 
(2014). A preliminary exploratory analysis in Appendix E showed that using a population 
prevalence baseline estimate to adjust FN and TN metrics can mimic the effect of complete 
follow-up. Supplemental Table 1 shows the original reported study values, population prevalence 
estimate matched by country and year and adjusted study metrics. Supplemental Figure 3, 4, and 
5 show sensitivity, specificity, and DOR that can be compared to original forest plots in figure 6, 
7, and 8 in the population based study section. This strategy was an idea taken from Barbaro et 
al. (2010) who used Australian prevalence estimate rates for ASD instead of following-up all 
negatives. After using their idea of population prevalence baseline, our largest study, 
Chlebowski, had adjusted sensitivity of 0.34 which closely resembles the follow-up adjusted 
metrics of the Guthrie study. More information on the preliminary exploratory analysis can be 
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observed in Appendix E. Guthrie leaves readers with the task of identifying new methods to 
detect a greater proportion of children with ASD.  
The studies included in this review were selected because the authors reported all TP, 
TN, FN, and FP data points. The main focus was to use clear psychometric data to calculate 
MADA while fitting the analysis into the timeline of a thesis. While these studies served their 
purpose of psychometric data reporting, some studies were found to lack positive qualities from 
an ASD identification process focus, based on Figure 1. Certain studies were noted during the 
QUADAS-2 process for not even including a flow chart, specifically Matson et al. (2013), Oien 
et al. (2018), Snow& Lecavalier (2008), and Toh et al. (2018) making it difficult to ensure 
numbers reported could be correctly replicated or when trying to understand the flow of their 
studies visually. QUADAS-2 drastically helped to pinpoint which domains this literature base 
needed improvement on; specifically Domain 4: “Flow and Timing” needed improvement 
because many studies resulted in high bias estimates (18/22, 81.8%) due to the amount of 
questions that had to be marked “unclear”. The QUADAS-2 covers all categories that need to be 
reviewed for collecting and reviewing studies for a meta-analysis. Besides Flow and Timing, 
results for the Domains: 1 Patient Selection and 2 Index Test were generally low bias while 
Domain 3: Reference Standard has a large number of unclear results as marked by this study. 
The QUADAS-2 review likely found more unclear results due to the ranking system modeled 
previously by Barger and redesigned for this study. Because of the strict guidelines of 
information to collection our focus on reference standard categories resulted in numerous high 
bias estimates as opposed to similar reviews that did not use strict methods.  
This study highlights a main area where research on the early identification process can 
improve: Clarity of reference standard reporting in all literature, particularly peer-reviewed 
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publications. Screening tools are an important aspect of early identification, but are most useful 
when predicting in a system with high quality diagnosis and long term ability to continue 
monitoring potential cases (Barger et al., 2018). Improvements to reference standard reporting in 
peer-reviewed articles can be seen in this study’s diagnostic framework which extends the 
QUADAS-2 by improving the categorical analysis in Domain 3: Reference Standard. This is 
done by creating specific and reproducible levels for bias estimates instead of general “low” or 
“high” bias labels. Thus, this framework might be useful for future meta-analysis studies or for 
the QUADAS-2 Appendix F to guide new bias categories this may reduce the amount of 
“unclear” answers for studies when performing a QUADAS-2 review for Domain 3. 
Systematic reviews and meta-analyses have tremendously helpful guidelines to follow (Pigott & 
Polanin, 2020; Polanin et al., 2019). The guidelines help keep the focus on the review question 
and therefore more able to answer the question. This study adds to systematic review methods by 
creating robust and defendable clinical reference standard categories that accounts for important 
insights about reference standard norms from the field of autism research. There may be more 
room for improvement since the original categories had to be modified to fit the data of this 
study, but disambiguating single clinician diagnosis from multi-clinician diagnosis is a valid 
change to the original format. Future direction should seek to use frameworks, such as seen in  
Figure 4 Redesigned Framework for Categorical Assessment of Reference Standards. It’s 
important for Categorical analysis that the meaning of a category is well defined which is not the 
case with QUADAS-2 Domain 3: Reference Standard questions. A more focused reference 
standard review can lead to better comparison of MADA results from other studies by 





 This study required a number of important methodological decisions, each with a 
potential limitation. First, M-CHAT studies vary in their choice cut-off rules and following up 
with positive and negative screens, and within text descriptions are often opaque. When 
available, we prioritized using flow charts to best determine identification procedures and 
interpret in-text descriptions; however, alternative approaches could be developed. In this review  
there are two studies that report two sample sets, Canal-Bedia et al. (2011) and Coelho-Medeiros 
et. al. (2019), because within-publication samples were collected independent of one another 
they are both reported and not expected to compromise findings. One major advantage of this 
work is that all studies used recommended M-CHAT cut-off scores (except Kamio) which likely 
helped control for a source of heterogeneity (Doebler & Bohning, 2010). The implications of 
including only studies that report all of their own metrics are that they can be misleading. 
Sensitivity and specificity from partial data across more studies can be back calculated which 
was not performed by this study to confirm the reported psychometric data reported. This would 
fill gaps in the current literature because this level of confirmation is not present in current 
MADA studies.  
The second important limitation is related to the number of primary studies that do not 
follow up all negative screens in order to determine the absolute number of false negatives that 
exist in their sample. In addition to not following up all negative screens, not all studies report 
sample demographics which may explain screening differences because individuals of different 
races have been shown to screen differently with the M-CHAT (Khowaja et al., 2015). This is an 
important methodological choice for study inclusion because this will positively bias 
psychometric results due to the likely under-identified number of cases reported in any given 
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study that does not follow-up completely. During the meta-regression there is indication that 
population based studies have significantly higher FPR which would the factor most affected by 
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Cross table and list of presumed outliers in the 
data
 
TP/TN outlier: Matson (150, 151) Hoang (129, 17021) Chlebowski (92, 18269) Oien (69, 67969) 
TP/FP outlier: Matson (150, 150) Hoang (129, 118) Chlebowski (92, 79) Oien (69, 1402) 
TP/FN outlier: Matson (150, 101) Hoang (129, 1) Chlebowski (92, 6) Oien (69, 228) 
TN/FP outlier: Oien (67969, 1402) 
TN/FN outlier: Oien (67969, 228) Matson (150, 101)  







Modified-Checklist for Autism in Toddlers 
M-CHAT 
Please fill out the following about how your child usually is. Please try to 
answer every question. If the behavior is rare (e.g., you've seen it once or 
twice), please answer as if the child does not do it. 
1.Does your child enjoy being swung, bounced on your knee, etc.? Yes No  
2.Does your child take an interest in other children? Yes No 
3.Does your child like climbing on things, such as up stairs? Yes No  
4.Does your child enjoy playing peek-a-boo/hide-and-seek? Yes No  
5.Does your child ever pretend, for example, to talk on the phone or take care 
of a doll or pretend other things? Yes No 
6.Does your child ever use his/her index finger to point, to ask for 
something? Yes No 
7.Does your child ever use his/her index finger to point, to indicate interest in 
something? Yes No 
8.Can your child play properly with small toys (e.g. cars or blocks) without 
just mouthing, fiddling, or dropping them? Yes No 
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9.Does your child ever bring objects over to you (parent) to show you 
something? Yes No 
10.Does your child look you in the eye for more than a second or two? Yes 
No 
11.Does your child ever seem oversensitive to noise? (e.g., plugging ears) 
Yes No 
12.Does your child smile in response to your face or your smile? Yes No 
13.Does your child imitate you? (e.g., you make a face-will your child imitate 
it?) Yes No 
14.Does your child respond to his/her name when you call? Yes No 
15.If you point at a toy across the room, does your child look at it? Yes No 
16.Does your child walk? Yes No 
17.Does your child look at things you are looking at? Yes No 
18.Does your child make unusual finger movements near his/her face? Yes 
No 
19.Does your child try to attract your attention to his/her own activity? Yes 
No  
20.Have you ever wondered if your child is deaf? Yes No 
21.Does your child understand what people say? Yes No 
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22.Does your child sometimes stare at nothing or wander with no purpose? 
Yes No 
23.Does your child look at your face to check your reaction when faced with 













QUADAS-2 Appendix F Questions 
Domain 1: Patient selection 
A. Risk of bias  





Was a consecutive or random sample of patients enrolled?  Yes / No / Unclear  
Was a case-control design avoided?  Yes / No / Unclear  
Did the study avoid inappropriate exclusions?  Yes / No / Unclear  
Could the selection of patients have introduced bias?  
Risk: Low / High / Unclear  
B. Concerns regarding applicability  




Is there concern that the included patients do not match the review question?  
Concern: Low / High / Unclear  
Domain 2: Index test(s) 
A. Risk of bias  







Were the index test results interpreted without knowledge of the results of 
the reference standard?  
Yes / No / 
Unclear  
If a threshold was used, was it pre-specified?  Yes / No / 
Unclear  
Could the conduct or interpretation of the index test have introduced bias?  
Risk: Low / High / Unclear  
B. Concerns regarding applicability  
Is there concern that the index test, its conduct, or interpretation differ from the review 
question?  
Concern: Low / High / Unclear  
Domain 3: Reference standard 
A. Risk of bias  





Is the reference standard likely to correctly classify the target condition?  Yes / No / 
Unclear  
Were the reference standard results interpreted without knowledge of the 
results of the index test?  
Yes / No / 
Unclear  
Could the reference standard, its conduct, or its interpretation have introduced bias?  
Risk: Low / High / Unclear  
B. Concerns regarding applicability  
Is there concern that the target condition as defined by the reference standard does not 
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match the review question?  
Concern: Low / High / Unclear  
Domain 4: Flow and timing 
A. Risk of bias  
Describe any patients who did not receive the index test(s) and/or reference standard or who 









Was there an appropriate interval between index test(s) and reference 
standard?  
Yes / No / Unclear  
Did all patients receive a reference standard?  Yes / No / Unclear  
Did patients receive the same reference standard?  Yes / No / Unclear  
Were all patients included in the analysis?  Yes / No / Unclear  
Could the patient flow have introduced bias?  






Population based and high-risk studies broken into reference standard categories 
Supplemental Figures 1 and 2 are the bivariate Reitsma illustrated by an SROC of 
subgroup analysis and clinical reference criteria. In Figure 17 Multi-Clinician reference standard 
shows a higher sensitivity than Other and neither are significantly different in FPR. In Figure 18 
Multi-Clinician reference standard has a higher sensitivity but Other appears to have a 
significantly better FPR. 
 
Supplemental Figure 1 








Supplemental Figure 2 







Exploratory Analysis of Population Based Estimate 
In figure 17 the original sensitivity metrics are compared to the adjusted sensitivity metrics. 
Between these two forest plots there are six studies whose metrics were adjusted: Chlebowski, 
Hoang, Kondolot, Oien, Oner, and Toh. Due to the nature of the adjustments all of these resulted 
in the sensitivity estimate being lowered, some of these were lowered significantly like 
Chlebowski from 0.93 to 0.34. Figure 22, shows similar changes but with specificity, these 
comparisons are interesting because the six studies where adjustments are made, no point 
estimates changed from the original study to the adjusted version. Figure 17, resembles more of 
figure 21, where the 6 studies whose metrics were adjusted changed. None were reduced to the 
point of being non-significant. The adjusted Se became 0.522 from the original of  0.746 and the 





Supplemental Table 1 
Adjusted identification metrics of population-based studies 
Author Country 
Pop. 











Baduel et al. 
(2017) France 1250 12 6 8 1201 18 2015 
Van Bakel et 
al. (2017) 0.00365 5 -13 6 No 1201 0.6667 0.993383 
Canal-Bedia et al. 
(2011) Spain 2055 23 0 25 2024 23 2007 
Adak & 
Halder (2017) 0.001297 3 -20 0 No 2024 1.00 0.987799 
Chlebowski, 
Robins, Barton, & 
Fein (2013) USA 18989 92 79 79 
1826
9 171 2012 
Baio et al. 
(2018) 0.014493 275 104 183 Yes 18165 0.3343 0.99567 
Coelho-Medeiros 
et al. (2019) Chile 100 1 90 1 0 17 2013 
Van Cong et 
al. (2015) 0.01 1 -16 0 No 90 1.00 0.989011 
Cuesta-gomez, 
Manzone, Posada-
De-La-Paz (2016) Argentina 420 1 0 1 402 1 2008 
Elsabbagh et 
al. (2012) 0.00131 1 0 0 No 402 1.00 0.997519 
Guthrie et al. 
(2019) USA 20375 205 249 1658 
1826
3 454 2014 
Baio et al. 
(2018) 0.016949 345 -109 249 No 18263 0.4515 0.916771 
Hoang et al. 
(2019) Vietnam 17754 129 1 118 
1702
1 130 2013 
Van Cong et 
al. (2015) 0.01 178 48 49 Yes 16973 0.7266 0.993096 
Kamio et al (2014) Japan 1851 20 22 24 1661 42 2008 
Kawamura et 
al. (2008) 0.01811 34 -8 22 No 1661 0.4762 0.985757 
Kerub et al (2018) Isreal 1591 7 3 43 1538 10 2001 
Davidovitch 




Supplemental Table 1 (Continued)        
Author Country 
Pop. 











Kondolot et al 
2016 Turkey 2021 2 0 15 2004 2 2013 
Van Cong et 
al. (2015) 0.01 20 18 18 Yes 1986 0.0989 0.992503 
Magan-Maganto 
et al (2018) Spain 3529 9 2 10 3485 11 2007 
Adak & 
Halder (2017) 0.001297 5 -6 2 No 3485 0.8182 0.997139 
Nygren et al 
(2012) Sweden 3985 33 15 3 3939 48 2010 
Fernell & 
Gillberg 
(2010) 0.0062 25 -23 15 No 3939 0.6875 0.999239 
Oien et al (2018) Norway 69668 69 228 1402 
6796
9 297 2010 
Posserud et 
al. (2010) 0.0087 606 309 537 Yes 67660 0.1138 0.979699 
Oner & Munir 
(2019) Turkey 6540 57 0 95 6388 57 2013 
Van Cong et 
al. (2015) 0.01 65 8 8 Yes 6380 0.8716 0.985327 
Toh, Tan, Lau, & 
Kiyu (2018) Malaysia 16297 18 32 20 
1622
7 50 2013 
Van Cong et 
al. (2015) 0.01 163 113 145 Yes 16114 0..1105 0.99876 
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Supplemental Figure 4 





Supplemental Figure 5 
Adjusted DOR Metrics of Population Based Studies by Population Prevalence Estimates 
 
 
